| pubmed-article:1524799 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1524799 | lifeskim:mentions | umls-concept:C0034493 | lld:lifeskim |
| pubmed-article:1524799 | lifeskim:mentions | umls-concept:C0033551 | lld:lifeskim |
| pubmed-article:1524799 | lifeskim:mentions | umls-concept:C1414500 | lld:lifeskim |
| pubmed-article:1524799 | lifeskim:mentions | umls-concept:C1514468 | lld:lifeskim |
| pubmed-article:1524799 | lifeskim:mentions | umls-concept:C1157325 | lld:lifeskim |
| pubmed-article:1524799 | lifeskim:mentions | umls-concept:C1314939 | lld:lifeskim |
| pubmed-article:1524799 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:1524799 | pubmed:dateCreated | 1992-10-22 | lld:pubmed |
| pubmed-article:1524799 | pubmed:abstractText | The mechanism whereby preconditioning with a transient period of ischemia renders the heart resistant to infarction from a subsequent ischemic insult is unknown. The purpose of this study was to determine whether cyclooxygenase pathways are involved in preconditioning's protection. Two inhibitors of that pathway, meclofenamate (MEC) and aspirin (ASP), were test in an in situ and a blood perfused isolated heart model, respectively. Preconditioning was achieved with 5 minute ischemia and 10 minutes reperfusion. All in situ hearts underwent 30 minute ischemia followed by 180 minute reperfusion, while the isolated hearts experienced 45 minute ischemia plus 120 minute reperfusion. Infarct size was measured with TTC stain. In the in situ model, 39.9% +/- 4.2% of the ischemic zone was infarcted in control hearts but only 8.8% +/- 2.2% in preconditioning hearts. Pretreatment with MEC (5 mg/Kg) caused no alteration of infarct size in either non preconditioned (34.3% +/- 8.3%) or preconditioned hearts (6.7% +/- 3.3%). In isolated hearts, 45 minute ischemia caused 31.0% +/- 5.9% of the ischemic zone to be infarcted in control hearts and only 5.4% +/- 2.2% in preconditioned hearts. Pretreatment with ASP (1 mg/Kg) failed to affect infarct size in either non preconditioned (35.7% +/- 3.7%) or preconditioned hearts (10.2% +/- 1.9%). The data indicate that cyclooxygenase pathways are not involved in the preconditioning's protection. | lld:pubmed |
| pubmed-article:1524799 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1524799 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1524799 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1524799 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1524799 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1524799 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1524799 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1524799 | pubmed:issn | 0887-8005 | lld:pubmed |
| pubmed-article:1524799 | pubmed:author | pubmed-author:DowneyJJ | lld:pubmed |
| pubmed-article:1524799 | pubmed:author | pubmed-author:LiuG SGS | lld:pubmed |
| pubmed-article:1524799 | pubmed:author | pubmed-author:StanleyA WAW | lld:pubmed |
| pubmed-article:1524799 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1524799 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:1524799 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1524799 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1524799 | pubmed:pagination | 157-64 | lld:pubmed |
| pubmed-article:1524799 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1524799 | pubmed:meshHeading | pubmed-meshheading:1524799-... | lld:pubmed |
| pubmed-article:1524799 | pubmed:meshHeading | pubmed-meshheading:1524799-... | lld:pubmed |
| pubmed-article:1524799 | pubmed:meshHeading | pubmed-meshheading:1524799-... | lld:pubmed |
| pubmed-article:1524799 | pubmed:meshHeading | pubmed-meshheading:1524799-... | lld:pubmed |
| pubmed-article:1524799 | pubmed:meshHeading | pubmed-meshheading:1524799-... | lld:pubmed |
| pubmed-article:1524799 | pubmed:meshHeading | pubmed-meshheading:1524799-... | lld:pubmed |
| pubmed-article:1524799 | pubmed:meshHeading | pubmed-meshheading:1524799-... | lld:pubmed |
| pubmed-article:1524799 | pubmed:meshHeading | pubmed-meshheading:1524799-... | lld:pubmed |
| pubmed-article:1524799 | pubmed:meshHeading | pubmed-meshheading:1524799-... | lld:pubmed |
| pubmed-article:1524799 | pubmed:meshHeading | pubmed-meshheading:1524799-... | lld:pubmed |
| pubmed-article:1524799 | pubmed:meshHeading | pubmed-meshheading:1524799-... | lld:pubmed |
| pubmed-article:1524799 | pubmed:meshHeading | pubmed-meshheading:1524799-... | lld:pubmed |
| pubmed-article:1524799 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1524799 | pubmed:articleTitle | Cyclooxygenase products are not involved in the protection against myocardial infarction afforded by preconditioning in rabbit. Cyclooxygenase pathway's involvement in preconditioning. | lld:pubmed |
| pubmed-article:1524799 | pubmed:affiliation | Kemp Carraway Heart Institute, Carraway Hospital, Birmingham, AL 35023. | lld:pubmed |
| pubmed-article:1524799 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1524799 | pubmed:publicationType | In Vitro | lld:pubmed |
